Mark Sheptoff Financial Planning’s Sarepta Therapeutics SRPT Stock Holding History

Mark Sheptoff Financial Planning’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.67K	Hold	260	–	–	﹤0.01%	454
2026 Q1	$5.67K	Hold	260	–	–	﹤0.01%	424
2025 Q4	$5.59K	Hold	260	–	–	﹤0.01%	421
2025 Q3	$5.01K	Buy	260 +200	+333%	+$3.56K	﹤0.01%	412
2025 Q2	$1.03K	Hold	60	–	–	﹤0.01%	488
2025 Q1	$3.83K	Hold	60	–	–	﹤0.01%	393
2024 Q4	$7.29K	Hold	60	–	–	﹤0.01%	338
2024 Q3	$7.49K	Hold	60	–	–	﹤0.01%	335
2024 Q2	$9.48K	Hold	60	–	–	0.01%	320
2024 Q1	$7.77K	Buy	+60	New	+$7.35K	﹤0.01%	310
2019 Q3	–	Sell	-100	Closed	-$15K	–	386
2019 Q2	$15K	Hold	100	–	–	0.01%	234
2019 Q1	$12K	Hold	100	–	–	0.01%	258
2018 Q4	$11K	Hold	100	–	–	0.01%	238
2018 Q3	$16K	Hold	100	–	–	0.01%	255
2018 Q2	$13K	Hold	100	–	–	0.01%	259
2018 Q1	$7K	Hold	100	–	–	﹤0.01%	319
2017 Q4	$6K	Hold	100	–	–	﹤0.01%	317
2017 Q3	$5K	Hold	100	–	–	﹤0.01%	323
2017 Q2	$3K	Buy	+100	New	+$3.26K	﹤0.01%	326

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Mark Sheptoff Financial Planning's SRPT Position: Q2 2026 in Review

Mark Sheptoff Financial Planning held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 260 shares worth $4.67K. The position accounts for ﹤0.01% of the portfolio, ranked #454.

Mark Sheptoff Financial Planning first reported a position in SRPT in Q2 2017 and has held it in 19 quarters since. The position peaked at $16K in Q3 2018. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Mark Sheptoff Financial Planning held 260 shares of Sarepta Therapeutics worth $4.67K as of Q2 2026.
Mark Sheptoff Financial Planning left its Sarepta Therapeutics share count unchanged in Q2 2026.
Sarepta Therapeutics made up ﹤0.01% of Mark Sheptoff Financial Planning's portfolio in Q2 2026, its #454 holding.
Mark Sheptoff Financial Planning first reported a position in Sarepta Therapeutics in Q2 2017 and has held it in 19 quarters since.
Mark Sheptoff Financial Planning's Sarepta Therapeutics position peaked at $16K in Q3 2018.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Mark Sheptoff Financial Planning's 13F filing for Q2 2026, filed 13 Aug 2026.